Workflow
Monte Rosa Therapeutics(GLUE)
icon
搜索文档
Monte Rosa Therapeutics (GLUE) Investor Presentation - Slideshow
2023-01-13 00:35
p-valuep-value Target A Target A Protein fold-change; (log2) Protein fold-change; (log2) 10 Proprietary AI/ML Engines Allow for Discovery of Glueable Targets and Highly Selective MGDs PPI propensity & pocket identification for reprogrammability E3 ligase surface evaluation Proteome-wide glueability assessment Surface complementarity connecting E3 ligases to neosubstrates Ternary complex modelling and in-silico screening Fast algorithms leveraging ensembles, dynamics and quantum mechanics Candidate neosubstr ...
Monte Rosa Therapeutics (GLUE) Investor Presentation - Slideshow
2022-06-14 02:15
| --- | --- | --- | --- | --- | |-------------------------------------------------------------|-------|-------|-------|--------------------------| | | | | | | | | | | | | | | | | | | | From Serendipity to Rational Design | | | | | | Taking Molecular Glue Degraders to New Heights \| June 2022 | | | | | | | | | | | | | | | | | | | | | | Monte Rosa l herapeutics | 2 | --- ...
Monte Rosa Therapeutics (GLUE) Investor Presentation - Slideshow
2022-04-15 02:45
From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | April 2022 Monte Rosa l herapeutics Forward-Looking Statements | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...
Monte Rosa Therapeutics (GLUE) Investor Presentation - Slideshow
2022-04-15 00:19
From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | April 2022 Monte Rosa l herapeutics Forward-Looking Statements | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...